Cost-effectiveness of zanubrutinib versus ibrutinib in the first-line treatment for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in China
Artículo
Acceso abierto
Artículo
DOAJ
Abstract Objective To evaluate the cost-effectiveness of zanubrutinib compared to ibrutinib in the first-line treatment of chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) from the perspective of the...
LCC TENDOk1lZGljaW5lIChHZW5lcmFsKQ~~Idioma eng
Acceso abiertoRuta libre sin proxy. Acceso recomendado cuando no hay suscripción activa.
Open Access